Loading
A phase 3 trial testing GFH375 in non-small-cell lung cancer, now recruiting.
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation is a phase 3 interventional study registered as NCT07668752, led by Genfleet Therapeutics (Shanghai), and recruiting on the registry. Official title: A Phase III, Randomised, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy. Planned enrolment is 300 participants (estimated). The study started in 2026-07-27 and primary completion is expected in 2030-06-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GFH375, GenFleet Therapeutics.
Shares GFH375, GenFleet Therapeutics.
Shares GFH375, GenFleet Therapeutics.
Shares GFH375, GenFleet Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/